Sanofi Innovation Awards

Sanofi iAwards: Call-for-Proposals

Each selected iAward project will receive:

- $125,000 research funding (including institutional indirect costs) for 12 months
- Sanofi scientific expertise, dedicated project management support and a scientific champion
- In-kind resources such as reagents, tool compounds, etc., if deemed necessary to advance the project
- Successful projects could be converted to SRAs and receive additional funding for 2-3 years

Areas of Interest
Sanofi is seeking the following type of opportunities in the therapeutic areas provided below:

- Early stage compounds, small molecules or biologics targeting novel disease mechanisms
- Disease relevant targets with validated mechanism of action
- Technology platforms with the potential to significantly improve drug discovery and development (examples – gene therapy, biologics development)
- Novel therapeutic modalities

IMMUNOLOGY & INFLAMMATION

- Diseases associated with dysregulated Type 2 immune responses including Atopic Dermatitis and Asthma
- Type 1/17 immune responses and Rheumatological disorders including Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Lupus Erythematosus, and IBD
- Autoimmune sequelae of checkpoint inhibition
- Co-stimulation and co-inhibitory pathways in autoimmune and allergic diseases
- Immune tolerance, organ-specific autoimmunity and emerging immunotherapies for autoimmune disease.
- Systems and computational immunology
- Immuno-metabolism

IMMUNO-ONCOLOGY

- Mechanisms of innate and acquired resistance to checkpoint blockade
- Immuno-modulatory function of CD38
- Immuno-modulatory function of TGFβ
- Immune cell engagers (NK cells & T cells engagers)
- Immuno-conjugates
- Novel ADC targets
- Intra-tumoral Treg depletion, modulation of immunosuppressive myeloid lineages
- Immune profiling methodologies in preclinical and clinical setting
- Novel translational models in IO

MOLECULAR ONCOLOGY

Sanofi priority indications are breast, lung, multiple myeloma, prostate but also could be other cancers pending on target or modality

- Novel targets and/or early drug discovery projects in molecularly-defined cancer populations and/or lineage
- Tumor induced immune-suppression: regulation of anti-tumor immunity when the target is located in tumor cells
- Tumors microenvironment targeting programs
- Modality: targeted protein degradation (PROTAC, Glue, monovalent degrader)

The deadline for submission to Innovation is June 4th, 2020.